SELLAS Life Sciences Group Inc. (NASDAQ:SLS) reported first-quarter (Q1) 2026 financial results on Tuesday while highlighting progress across its acute myeloid leukemia (AML) pipeline.
CEO Angelos Stergiou said the company continued advancing its clinical programs during the quarter while preparing for the anticipated data readout from its pivotal Phase 3 REGAL study
SELLAS will release the upcoming data after the study reaches its pre-specified 80th event threshold — a major milestone for the company. Read Also: AstraZeneca’s Rare Disease Drug Shows Reduced Dependence On Calcium Supplements REGAL Trial Approaches Final Event Threshold SELLAS said the ongoing Phase 3 REGAL trial is evaluating GPS in AML patients who achieved complete remission following second-line salvage therapy. As of May 11, the study had recorded 78 events.
Reaching 80 events will initiate database lock procedures, blinded data review, statistical analysis, and eventual topline disclosure. The company said it plans to provide another update once the final event threshold has been reached. SLS009 Expands Into Earlier-Line AML Treatment SELLAS also highlighted progress with SLS009, including the launch of an 80-patient Phase 2 study in newly diagnosed AML patients considered unlikely to benefit from standard therapies such as AZA/VEN treatment.